Department of Pediatrics, University of Groningen, University Medical Center Groningen, the Netherlands.
Department of Pediatrics, University of Groningen, University Medical Center Groningen, the Netherlands.
Early Hum Dev. 2020 Aug;147:105075. doi: 10.1016/j.earlhumdev.2020.105075. Epub 2020 May 18.
Selective serotonin reuptake inhibitors (SSRIs) are prescribed in 2-8% during pregnancy. Whether prenatal exposure to SSRIs has long-term effects on the children's development is unknown.
The aim of this study was to determine the effect of prenatal exposure to SSRIs on children's cognitive, motor, and behavioral outcomes at 2.5 years, adjusted for maternal depression and anxiety.
In a prospective, longitudinal cohort-study we included 111 pregnant women treated either or not with an SSRI. We examined cognitive and motor development of their children at 2.5 years, using the Bayley Scale of Infant and Toddler Development, 3rd Edition, and measured emotional and behavioral problems using the parent-rated Child Behavior Checklist (CBCL). Maternal depression and anxiety was determined during pregnancy and at the children's assessment. Differences of normed cognitive, motor, and behavioral scores between SSRI-exposed and non-SSRI-exposed children were tested using multiple linear regression analyses.
We examined 102 children. SSRI-exposed children had lower scaled scores on cognition and gross motor development than non-SSRI-exposed children: 9.0 ± 1.4 (mean ± SD) versus 9.9 ± 1.7 [P = 0.004], and 7.9 ± 2.2 versus 9.0 ± 2.5 [P = 0.01], respectively. Differences remained significant after adjusting for maternal depression and anxiety and other confounders in various models (mean difference for cognition 0.8 to 0.9 points, for gross motor 1.1 to 1.2 points). Only after adjusting for severity of maternal anxiety, differences in gross motor scores lost significance.
Prenatal exposure to SSRIs is associated with poorer cognitive and gross motor development of the children at 2.5 years. Effects on gross motor development disappeared after correction for severity of maternal anxiety.
选择性 5-羟色胺再摄取抑制剂(SSRIs)在怀孕期间的使用率为 2-8%。产前暴露于 SSRIs 是否会对儿童的发育产生长期影响尚不清楚。
本研究旨在确定产前暴露于 SSRIs 是否会影响儿童在 2.5 岁时的认知、运动和行为结果,同时调整了母亲的抑郁和焦虑情况。
在一项前瞻性、纵向队列研究中,我们纳入了 111 名接受或未接受 SSRIs 治疗的孕妇。我们使用贝利婴幼儿发育量表第 3 版评估了他们孩子在 2.5 岁时的认知和运动发育,并使用父母评定的儿童行为检查表(CBCL)测量了情绪和行为问题。在怀孕期间和儿童评估时评估了母亲的抑郁和焦虑情况。使用多元线性回归分析测试了 SSRI 暴露组和非 SSRI 暴露组儿童之间标准化认知、运动和行为评分的差异。
我们共检查了 102 名儿童。SSRI 暴露组儿童的认知和粗大运动发育评分低于非 SSRI 暴露组儿童:9.0±1.4(均值±标准差)与 9.9±1.7[P=0.004],7.9±2.2 与 9.0±2.5[P=0.01]。在调整了母亲的抑郁和焦虑以及其他混杂因素的各种模型中,差异仍然显著(认知的平均差异为 0.8 至 0.9 分,粗大运动的平均差异为 1.1 至 1.2 分)。仅在调整了母亲焦虑严重程度后,粗大运动评分的差异才失去了显著性。
产前暴露于 SSRIs 与儿童在 2.5 岁时的认知和粗大运动发育较差相关。在对母亲焦虑严重程度进行校正后,对粗大运动发育的影响消失了。